Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2006

Open Access 01-12-2006 | Research article

Heat shock protein expression in canine malignant mammary tumours

Authors: Mariarita Romanucci, Alessia Marinelli, Giuseppe Sarli, Leonardo Della Salda

Published in: BMC Cancer | Issue 1/2006

Login to get access

Abstract

Background

Abnormal levels of Heat Shock Proteins (HSPs) have been observed in many human neoplasms including breast cancer and it has been demonstrated that they have both prognostic and therapeutic implications. In this study, we evaluated immunohistochemical expression of HSPs in normal and neoplastic canine mammary glands and confronted these results with overall survival (OS), in order to understand the role of HSPs in carcinogenesis and to establish their potential prognostic and/or therapeutic value.

Methods

Immunohistochemical expression of Hsp27, Hsp72, Hsp73 and Hsp90 was evaluated in 3 normal canine mammary glands and 30 malignant mammary tumours (10 in situ carcinomas, 10 invasive carcinomas limited to local structures without identifiable invasion of blood or lymphatic vessels, 10 carcinomas with invasion of blood or lymphatic vessels and/or metastases to regional lymph nodes). A semi-quantitative method was used for the analysis of the results.

Results

Widespread constitutive expression of Hsp73 and Hsp90 was detected in normal tissue, Hsp72 appeared to be focally distributed and Hsp27 showed a negative to rare weak immunostaining. In mammary tumours, a significant increase in Hsp27 (P < 0.01), Hsp72 (P < 0.05) and Hsp90 (P < 0.01) expression was observed as well as a significant reduction in Hsp73 (P < 0.01) immunoreactivity compared to normal mammary gland tissue. Hsp27 demonstrated a strong positivity in infiltrating tumour cells and metaplastic squamous elements of invasive groups. High Hsp27 expression also appeared to be significantly correlated to a shorter OS (P = 0.00087). Intense immunolabelling of Hsp72 and Hsp73 was frequently detected in infiltrative or inflammatory tumour areas. Hsp90 expression was high in all tumours and, like Hsp73, it also showed an intense positivity in lymphatic emboli.

Conclusion

These results suggest that Hsp27, Hsp72 and Hsp90 are involved in canine mammary gland carcinogenesis. In addition, Hsp27 appears to be implicated in tumour invasiveness and its high immunodetection in invasive tumours is indicative of a poorer clinical outcome.
Appendix
Available only for authorised users
Literature
1.
Whitley D, Goldberg SP, Jordan WD: Heat shock proteins: a review of the molecular chaperones. J Vasc Surg. 1999, 29: 748-751. 10.1016/S0741-5214(99)70329-0.CrossRefPubMed
2.
Ciocca DR, Oesterreich S, Chamness GC, McGuire WL, Fuqua SAW: Biological and clinical implications of heat shock protein 27000 (Hsp27): a review. J Natl Cancer Inst. 1993, 85: 1558-1570.CrossRefPubMed
3.
Welch WJ: Mammalian stress response: cell physiology, structure/function of stress proteins, and implications for medicine and disease. Physiol Rev. 1992, 72: 1063-1081.PubMed
4.
Lai BT, Chin NW, Stanek AE, Ke W, Lannks KW: Quantitation and intracellular localization of the 85 kDa heat shock protein by using monoclonal and polyclonal antibodies. Mol Cell Biol. 1984, 4: 2802-2819.CrossRefPubMedPubMedCentral
5.
Sreedhar AS, Kalmar E, Csermaly P, Shen Y: Hsp90 isoforms: functions, expression and clinical importance. FEBS Lett. 2004, 562: 11-15. 10.1016/S0014-5793(04)00229-7.CrossRefPubMed
6.
Ciocca DR, Calderwood SK: Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones. 2005, 10: 86-103. 10.1379/CSC-99r.1.CrossRefPubMedPubMedCentral
7.
8.
Thor A, Benz C, Moore D, Goldman E, Edgerton S, Landry J, Schwartz L, Mayall B, Hickey E, Weber LA: Stress response protein (srp-27) determination in primary human breast carcinomas: clinical, histologic, and prognostic correlations. J Natl Cancer Inst. 1991, 83: 170-178.CrossRefPubMed
9.
Ciocca DR, Clark GM, Tandon AK, Fuqua SAW, Welch WJ, McGuire WL: Heat shock protein Hsp70 in patients with axillary lymph node-negative breast cancer: prognostic implications. J Natl Cancer Inst. 1993, 85: 570-574.CrossRefPubMed
10.
Hurlimann J, Gebhard S, Gomez F: Oestrogen receptor, progesterone receptor, pS2, Erd5, Hsp27 and cathepsin D in invasive ductal breast carcinomas. Histopathology. 1993, 23: 239-248.CrossRefPubMed
11.
Ioachim E, Tsanou E, Briasoulis E, Batsis Ch, Karavasilis V, Charchanti A, Pavlidis N, Agnantis NJ: Clinicopathological study of the expression of hsp27, pS2, cathepsin D and metallothionein in primary invasive breast cancer. Breast. 2003, 12: 111-119. 10.1016/S0960-9776(02)00290-4.CrossRefPubMed
12.
Jameel A, Skilton RA, Campbell TA, Chander SK, Coombes RC, Luqmani YA: Clinical and biological significance of Hsp89 alpha in human breast cancer. Int J Cancer. 1992, 50: 409-415.CrossRefPubMed
13.
14.
Têtu B, Brisson J, Landry J, Huot J: Prognostic significance of heat-shock protein-27 in node-positive breast carcinoma: an immunohistochemical study. Breast Cancer Res Treat. 1995, 36: 93-97. 10.1007/BF00690189.CrossRefPubMed
15.
Oesterreich S, Hilsenbeck SG, Ciocca DR, Allred DC, Clark GM, Chamness GC, Osborne CK, Fuqua SAW: The small heat shock protein Hsp27 is not an independent prognostic marker in axillary lymph node-negative breast cancer patients. Clin Cancer Res. 1996, 2: 1199-1206.PubMed
16.
Thanner F, Sütterlin MW, Kapp M, Rieger L, Kristen P, Dieti J, Gassel AM, Müller T: Heat-shock protein 70 as a prognostic marker in node-negative breast cancer. Anticancer Res. 2003, 23: 1057-1062.PubMed
17.
Thanner F, Sutterlin MW, Kapp M, Rieger L, Morr AK, Kristen P, Dietl J, Gassel AM, Muller T: Heat shock protein 27 is associated with decreased survival in node-negative breast cancer patients. Anticancer Res. 2005, 25: 1649-1653.PubMed
18.
Ciocca DR, Green S, Elledge RM, Clark GM, Pugh R, Ravdin P, Lew D, Martino S, Osborne CK: Heat shock proteins hsp27 and hsp70: lack of correlation with response to tamoxifen and clinical course of disease in estrogen receptor-positive metastatic breast cancer (A Southwest Oncology Group Study). Clin Cancer Res. 1998, 4: 1263-1266.PubMed
19.
Fuqua SAW, Oesterreich S, Hilsenbeck SG, Von Hof DD, Eckardt J, Osborne CK: Heat shock proteins and drug resistance. Breast Cancer Res Treat. 1994, 32: 67-71. 10.1007/BF00666207.CrossRefPubMed
20.
Vargas-Roig LM, Gago FE, Tello O, Aznar JC, Ciocca DR: Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy. Int J Cancer. 1998, 79: 468-475. 10.1002/(SICI)1097-0215(19981023)79:5<468::AID-IJC4>3.0.CO;2-Z.CrossRefPubMed
21.
Nylandsted J, Wick W, Hirt UA, Brand K, Rohde M, Leist M, Weller M, Jäättelä M: Eradication of glioblastoma, and breast and colon carcinoma xenografts by Hsp70 depletion. Cancer Res. 2002, 62: 7139-7142.PubMed
22.
Bagatell R, Whitesell L: Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol Cancer Ther. 2004, 3: 1021-1030.CrossRefPubMed
23.
Faure O, Graff-Dubois S, Bretaudeau L, Derré L, Gross DA, Alves PMS, Cornet S, Duffour MT, Chouaib S, Miconnet I, Gregoire M, Jotereau F, Lemonnier FA, Abastado JP, Kosmatopoulos K: Inducible Hsp70 as target of anticancer immunotherapy: Identification of HLA-A*0201-restricted epitopes. Int J Cancer. 2004, 108: 863-870. 10.1002/ijc.11653.CrossRefPubMed
24.
Kim JH, Majumder N, Lin H, Chen J, Falo LD, You Z: Enhanced immunity by NeuEDhsp70 DNA vaccine is needed to combat an aggressive spontaneous metastatic breast cancer. Mol Ther. 2005, 11: 941-949. 10.1016/j.ymthe.2005.01.003.CrossRefPubMed
25.
Miyata Y: Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents. Curr Pharm Des. 2005, 11: 1131-1138. 10.2174/1381612053507585.CrossRefPubMed
26.
Soti C, Nagy E, Giricz Z, Vígh L, Csermely P, Ferdinandy P: Heat shock proteins as emerging therapeutic targets. Br J Pharmacol. 2005, 146: 769-780. 10.1038/sj.bjp.0706396.CrossRefPubMedPubMedCentral
27.
Misdorp W: Tumors of the mammary gland. Tumors in domestic animals. Edited by: Meuten DJ. 2002, Ames: Iowa State Press, 575-606. 4
28.
Nieto A, Peña L, Pérez-Alenza MD, Sánchez MA, Flores JM, Castaño M: Immunohistochemical detection of estrogen receptor alpha in canine mammary tumors: clinical and pathologic associations and prognostic significance. Vet Pathol. 2000, 37: 239-247. 10.1354/vp.37-3-239.CrossRefPubMed
29.
Misdorp W, Else RW, Hellmén E, Lipscomb TP: Histological classification of mammary tumors of the dog and the cat. 2nd series. 1999, World Health Organization AFIP. Washington: DC, 7:
30.
Gilbertson SR, Kurzman D, Zachrau RE, Hurvitz AI, Black MM: Canine mammary epithelial neoplasms: biological implications of morphologic characteristics assessed in 232 dogs. Vet Pathol. 1983, 20: 127-142.CrossRefPubMed
31.
Yano M, Naito Z, Yokoyama M, Shiraki Y, Ishiwata T, Inokuchi M, Asano G: Expression of Hsp90 and Cyclin D1 in human breast cancer. Cancer Lett. 1999, 137: 45-51. 10.1016/S0304-3835(98)00338-3.CrossRefPubMed
32.
Helmbrecht K, Zeise E, Reinsing L: Chaperones in cell cycle regulation and mitogenic signal transduction: a review. Cell Prolif. 2000, 33: 341-365. 10.1046/j.1365-2184.2000.00189.x.CrossRefPubMed
33.
Grammatikakis N, Lin J, Grammatikakis A, Tsichlis PN, Cochran BH: p50cdc37 acting in concert with Hsp90 is required for Raf-1 function. Mol Cell Biol. 1999, 19: 1661-1672.CrossRefPubMedPubMedCentral
34.
Aligue R, Akhavan-Niak H, Russel P: A role for Hsp90 in cell cycle control: Wee1 tyrosine kinase activity requires interaction with Hsp90. EMBO J. 1994, 13: 6099-6106.PubMedPubMedCentral
35.
Sato S, Fujita N, Tsuruo T: Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci USA. 2000, 97: 10832-10837. 10.1073/pnas.170276797.CrossRefPubMedPubMedCentral
36.
Pratt WB, Toft DO: Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev. 1997, 18: 306-360. 10.1210/er.18.3.306.PubMed
37.
Xu W, Mimnaugh E, Rosser MFN, Nicchitta C, Marcu M, Yarden Y, Neckers L: Sensitivity of mature ErbB2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. J Biol Chem. 2001, 276: 3702-3708. 10.1074/jbc.M006864200.CrossRefPubMed
38.
Ahern TE, Bird RC, Bird AC, Wolfe LG: Expression of the oncogene c-erbB-2 in canine mammary cancers and tumour-derived cell lines. Am J Vet Res. 1996, 57: 693-696.PubMed
39.
Matsuyama S, Nakamura M, Yonezawa K, Shimada T, Ohashi F, Takamori Y, Kubo K: Expression patterns of the erbB subfamily mRNA in canine benign and malignant mammary tumors. J Vet Med Sci. 2001, 63: 949-954. 10.1292/jvms.63.949.CrossRefPubMed
40.
Martin de las Mulas J, Ordas J, Millan Y, Fernandez-Soria V, Ramon y Cajal S: Oncogene HER-2 in canine mammary gland carcinomas: an immunohistochemical and chromogenic in situ hybridization study. Breast Cancer Res Treat. 2003, 80: 363-367. 10.1023/A:1024929730165.CrossRefPubMed
41.
Dutra AP, Grana NV, Schmitt FC, Cassali GD: c-erbB-2 expression and nuclear pleomorphism in canine mammary tumors. Braz J Med Biol Res. 2004, 37: 1673-1681. 10.1590/S0100-879X2004001100013.CrossRefPubMed
42.
Gress MT, Muller-Pillasch F, Weber C, Lerch MM, Friess H, Buchler M, Beger HG, Adler G: Differential expression of heat shock proteins in pancreatic carcinoma. Cancer Res. 1994, 54: 547-551.PubMed
43.
Yufu Y, Nishimura J, Nawata H: High constitutive expression of heat shock protein 90 alpha in human acute leukaemia cells. Leuk Res. 1992, 16: 597-605. 10.1016/0145-2126(92)90008-U.CrossRefPubMed
44.
Münster PN, Srethapakdi M, Moasser MM, Rosen N: Inhibition of heat shock protein 90 function by Ansamycins causes the morphological and functional differentiation of breast cancer cells. Cancer Res. 2001, 61: 2945-2952.PubMed
45.
Beliakoff J, Bagatell R, Paine-Murrieta G, Taylor CW, Lykkesfeldt AE, Whitesell L: Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors. Clin Cancer Res. 2003, 9: 4961-4971.PubMed
46.
Solit DB, Basso AD, Olshen AB, Scher HI, Rosen N: Inhibition of heat shock protein 90 function down-regulates akt kinase and sensitizes tumors to taxol. Cancer Res. 2003, 63: 2139-2144.PubMed
47.
Bull EE, Dote H, Brady KJ, Burgan WE, Carter DJ, Cerra MA, Oswald KA, Hollingshead MG, Camphausen K, Tofilon PJ: Enhanced tumour cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin. Clin Cancer Res. 2004, 10: 8077-8084. 10.1158/1078-0432.CCR-04-1212.CrossRefPubMed
48.
Bagatell R, Khan O, Paine-Murrieta G, Taylor CW, Akinanga S, Whitesell L: Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer. Clin Cancer Res. 2001, 7: 2076-2084.PubMed
49.
Kumaraguruparan R, Karunagaran D, Balachandran C, Manohar BM, Nagini S: Of humans and canines: a comparative evaluation of heat shock and apoptosis-associated proteins in mammary tumors. Clin Chim Acta. 2005, 365: 168-176. 10.1016/j.cca.2005.08.018.CrossRefPubMed
50.
Cardoso F, Di Leo A, Larsimont D, Gancberg D, Rouas G, Dolci S, Ferriera F, Paesmans M, Piccart M: Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes. Ann Oncol. 2001, 12: 615-620. 10.1023/A:1011182524684.CrossRefPubMed
51.
Goetz MP, Toft D, Reid J, Ames M, Stensgard B, Safgren S, Adjei AA, Sloan J, Atherton P, Vasile V, Salazaar S, Adjei A, Croghan G, Erlichman C: Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol. 2005, 23: 1078-1087. 10.1200/JCO.2005.09.119.CrossRefPubMed
52.
Ramanathan RK, Trump DL, Eiseman JL, Belani CP, Agarwala SS, Zuhowski EG, Lan J, Potter DM, Ivy SP, Ramalingam S, Brufsky AM, Wong MK, Tutchko S, Egorin MJ: Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res. 2005, 11: 3385-3391. 10.1158/1078-0432.CCR-04-2322.CrossRefPubMed
53.
Whitesell L, Lindquist SL: Hsp90 and the chaperoning of cancer. Nat Rev Cancer. 2005, 5: 761-772. 10.1038/nrc1716.CrossRefPubMed
54.
Price JT, Quinn JM, Sims NA, Vieusseux J, Waldeck K, Docherty SE, Myers D, Nakamura A, Waltham MC, Gillespie MT, Thompson EW: The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamicin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line. Cancer Res. 2005, 65: 4929-4934. 10.1158/0008-5472.CAN-04-4458.CrossRefPubMed
55.
de Carcer G: Heat shock protein 90 regulates the metaphase-anaphase transition in a polo-like kinase-dependent manner. Cancer Res. 2004, 64: 5106-5112. 10.1158/0008-5472.CAN-03-2214.CrossRefPubMed
56.
de Carcer G, do Carmo Avides M, Lallena MJ, Glover DM, Gonzalez G: Requirement of Hsp90 for centrosomal function reflects its regulation of Polo kinase stability. EMBO J. 2001, 20: 2878-2884. 10.1093/emboj/20.11.2878.CrossRefPubMedPubMedCentral
57.
Agueli C, Geraci F, Giudice G, Cimenti L, Cascino D, Sconzo G: A constitutive 70 kDa heat shock protein is localized on the fibres of spindles and asters at metaphase in an ATP-dependent manner: a new role is proposed. Biochem J. 2001, 360: 413-419. 10.1042/0264-6021:3600413.CrossRefPubMedPubMedCentral
58.
Liao J, Lowthert LA, Ghori N, Omary MB: The 70-kDa heat shock proteins associate with glandular intermediate filaments in an ATP-dependent manner. J Biol Chem. 1995, 270: 915-922. 10.1074/jbc.270.2.915.CrossRefPubMed
59.
Jolly C, Morimoto RI: Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J Natl Cancer Inst. 2000, 92: 1564-1572. 10.1093/jnci/92.19.1564.CrossRefPubMed
60.
Moseley PL: Heat shock proteins and the inflammatory response. Ann N Y Acad Sci. 1998, 856: 206-213. 10.1111/j.1749-6632.1998.tb08327.x.CrossRefPubMed
61.
Polla BS, Bachelet M, Elia G, Santoro MG: Stress proteins in inflammation. Ann N Y Acad Sci. 1998, 851: 75-85. 10.1111/j.1749-6632.1998.tb08979.x.CrossRefPubMed
62.
Devaja O, King RJB, Papadopoulos A, Raju KS: Heat-shock protein 27 (Hsp27) and its role in female reproductive organs. Eur J Gynaecol Oncol. 1997, 18: 16-22.PubMed
63.
Takahashi S, Narimatsu E, Asanuma H, Okazaki M, Okazaki A, Hirata K, Mori M, Chiba T, Sato N, Kikuchi K: Immunohistochemical detection of estrogen receptor in invasive human breast cancer: correlation with heat shock proteins, pS2 and oncogene products. Oncology. 1995, 52: 371-375.CrossRefPubMed
64.
Laguens GE, Coronato S, Spinelli O, Laguens RP, Di Girolamo W: Can breast cancer Hsp27 (Heat Shock Protein 27000) expression influence axillary lymph node status?. Breast. 2001, 10: 179-181. 10.1054/brst.2000.0221.CrossRefPubMed
65.
Lemieux P, Oesterreich S, Lawrence JA, Steeg PS, Hilsenbeck SG, Harvey JM, Fuqua SAW: The small heat shock protein hsp27 increases invasiveness but decreases motility of breast cancer cells. Invasion Metastasis. 1997, 17: 113-123.PubMed
66.
Rust W, Kingsley K, Petnick T, Padmanabhan S, Carper SW, Plopper GE: Heat shock protein 27 plays two distinct roles in controlling human breast cancer cell migration on Laminin-5. Mol Cell Biol Res Commun. 1999, 1: 196-202. 10.1006/mcbr.1999.0130.CrossRefPubMed
67.
Shin KD, Lee MY, Shin DS, Lee S, Son KH, Koh S, Paik YK, Kwon BM, Han DC: Blocking tumor cell migration and invasion with biphenyl isoxazole derivative KRIBB3, a synthetic molecule that inhibits Hsp27 phosphorylation. J Biol Chem. 2005, 280: 41439-41448. 10.1074/jbc.M507209200.CrossRefPubMed
68.
Lambert H, Charette SJ, Bernier AF, Guimond A, Landry J: Hsp27 multimerization mediated by phosphorylation-sensitive intermolecular interactions at the amino terminus. J Biol Chem. 1999, 274: 9378-9385. 10.1074/jbc.274.14.9378.CrossRefPubMed
69.
Gusev NB, Bogatcheva NV, Marston SB: Structure and properties of small heat shock proteins (sHsp) and their interaction with cytoskeleton proteins. Biochemistry (Mosc). 2002, 67: 511-519. 10.1023/A:1015549725819.CrossRef
70.
Mounier N, Arrigo A: Actin cytoskeleton and small heat shock proteins: how do they interact?. Cell Stress Chaperones. 2002, 7: 167-176. 10.1379/1466-1268(2002)007<0167:ACASHS>2.0.CO;2.CrossRefPubMedPubMedCentral
71.
Vanmuylder N, Evrard L, Daelemans P, Dourov N: Chaperones in the parotid gland: localization of heat shock proteins in human adult salivary gland. Cells Tissues Organs. 2000, 167: 199-205. 10.1159/000016782.CrossRefPubMed
72.
Yaziji H, Gown AM, Sneige N: Detection of stromal invasion in breast cancer: the myoepithelial markers. Adv Anat Pathol. 2000, 7: 100-109.CrossRefPubMed
73.
Romanucci M, Bongiovanni L, Marruchella G, Marà M, Di Guardo G, Preziosi R, Della Salda L: Heat shock proteins (HSPs) expression in canine intracutaneous cornifying epithelioma and squamous cell carcinoma. Vet Dermatol. 2005, 16: 108-116. 10.1111/j.1365-3164.2005.00436.x.CrossRefPubMed
74.
Hell-Pourmojib M, Neuner P, Fischer H, Rezaie S, Kindås-Mügge I, Knobler R, Trautinger F: Differential expression of a novel gene in response to Hsp27 and cell differentiation in human keratinocytes. J Invest Dermatol. 2002, 119: 154-159. 10.1046/j.1523-1747.2002.01793.x.CrossRefPubMed
75.
Jonak C, Klosner G, Kokesch C, Födinger D, Hönigsmann H, Trautinger F: Subcorneal colocalization of the small heat shock protein, Hsp27, with keratins and proteins of the cornified cell envelope. Br J Dermatol. 2002, 147: 13-19. 10.1046/j.1365-2133.2002.04667.x.CrossRefPubMed
Metadata
Title
Heat shock protein expression in canine malignant mammary tumours
Authors
Mariarita Romanucci
Alessia Marinelli
Giuseppe Sarli
Leonardo Della Salda
Publication date
01-12-2006
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2006
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-6-171

Other articles of this Issue 1/2006

BMC Cancer 1/2006 Go to the issue

Research article

Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers

Research article

A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck

Research article

MUC1 expression and anti-MUC1 serum immune response in head and neck squamous cell carcinoma (HNSCC): a multivariate analysis

Research article

BCR and its mutants, the reciprocal t(9;22)-associated ABL/BCR fusion proteins, differentially regulate the cytoskeleton and cell motility

Research article

Fluorescence in situhybridization (FISH) analysis of primary ocular adnexal MALT lymphoma

Case report

The carcinogenic potential of tacrolimus ointment beyond immune suppression: a hypothesis creating case report
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits